Halozyme names Darren Snellgrove as CFO, effective June 8, 2026

HALOZYME THERAPEUTICS, INC.

Darren Snellgrove appointed CFO effective June 8, 2026; previously VP IR at Johnson & Johnson and CFO of its Pharmaceuticals sector.
Compensation: $670,000 annual salary, 50% bonus target, $350,000 sign-on cash bonus, and $7.2M new-hire equity awards ($3.2M RSUs + $4M options).
2027 long-term incentive minimum $4M; make-whole RSUs vest over 3 years, stock options vest 25% after 1 year then monthly.
David Ramsay, interim CFO, will assume advisory role effective June 8, 2026 to assist transition.
Snellgrove holds MBA from Villanova, BA from University of Southampton; no family relationships or material interests in transactions.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

David Ramsay

Interim CFO

HALO · HALOZYME THERAPEUTICS, INC.

Effective: 2026-06-08
Filed: April 30, 2026, 7:59 PM ET

Effective as of June 8, 2026, David Ramsay, the Company’s current Interim CFO, will assume an advisory role with the Company to assist during a brief transition period.

Appointed

Darren Snellgrove

Chief Financial Officer

HALO · HALOZYME THERAPEUTICS, INC.

Effective: 2026-06-08
Filed: April 30, 2026, 7:59 PM ET

On April 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that Darren Snellgrove has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), effective June 8, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

David Ramsay changed role as Interim CFO at HALOZYME THERAPEUTICS, INC..

Action: will assume an advisory role
Role: Interim CFO

Exact text from the filing

Effective as of June 8, 2026, David Ramsay, the Company’s current Interim CFO, will assume an advisory role with the Company to assist during a brief transition period.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Darren Snellgrove was appointed as Chief Financial Officer at HALOZYME THERAPEUTICS, INC..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On April 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that Darren Snellgrove has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), effective June 8, 2026.

View on SEC.gov

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-26-000053

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.